Clover Health Investments Corp (CLOV)
Official siteHEALTHCARE • HEALTHCARE PLANS • NASDAQ
Market Cap: $2.66B
Last updated: Nov 17, 2026 at 11:05 AM ET
Clover Health Investments Corp (CLOV) P/E Ratio & Valuation Multiples
Clover Health Investments (CLOV) trades at 123.8x trailing earnings and 1.0x sales. Its P/S of 1.0x is above its 5-year median of 0.7x. Its forward P/E is 37.7x. The median P/E across 12 similar companies is 28.4x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 228.4% higher over the next year. Its free cash flow yield is 5.0%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 123.8x |
| Forward P/E | 37.7x |
| Price to sales | 1.0x |
| Price to book | 6.7x |
| EV/EBITDA | 185.4x |
| Price to FCF | 19.9x |
| EV/FCF | 17.9x |
| PEG | N/A |
| FCF yield | 5.0% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.0x | 0.7x | N/A |
| P/B | 6.7x | 3.0x | N/A |
Valuation History
Over the 5 of the 6 year ends shown that have a P/S, its P/S ranged from 0.4x in 2023 to 1.1x in 2024.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $2.35 | 0.6x | 3.9x |
| 2024 | $3.15 | 1.1x | 4.5x |
| 2023 | $0.95 | 0.4x | 1.6x |
| 2022 | $0.93 | 0.4x | 1.2x |
| 2021 | $3.72 | 1.1x | 3.3x |
| 2020 | $16.77 | N/A | N/A |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CLOV
What is CLOV's forward P/E ratio?
Clover Health Investments has a forward P/E ratio of 37.7x.
Is CLOV stock overvalued?
GNG's valuation label for CLOV is Overvalued. Its P/E of 123.8x compares with a median of 28.4x across 12 similar companies.
What is CLOV's price to sales ratio?
Clover Health Investments has a price to sales ratio of 1.0x.
CLOV pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors